Loading
Loading
Cognitive & Nootropic · 10mg
Janoshik-tested · 10 vials per kit
PE-22-28 is a synthetic peptide TREK-1 potassium channel inhibitor studied in preclinical research for its antidepressant and neuroprotective properties. Research has examined its potential to modulate TREK-1 channel activity involved in depression pathways, enhance synaptic plasticity, and produce rapid antidepressant-like effects in animal models. Studies have explored applications in treatment-resistant depression and neuroinflammation models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
PE-22-28
Spadin C-Terminal Fragment
PE-22-28 is a synthetic hexapeptide derived from the C-terminal region of spadin, a naturally occurring 17-amino-acid peptide produced by cleavage of the propeptide domain of neurotensin receptor 3 (NTSR3/sortilin). PE-22-28 represents the minimal active fragment of spadin with potent TREK-1 blocking activity and rapid-onset antidepressant-like effects in animal models.
PE-22-28 is a selective blocker of TREK-1 (TWIK-related K+ channel 1), a mechanosensitive, thermosensitive, and anaesthetic-sensitive background potassium channel expressed predominantly in hippocampal neurons. TREK-1 overactivity is associated with depression — TREK-1 knockout mice exhibit an antidepressant phenotype. By blocking TREK-1, PE-22-28 increases neuronal excitability in limbic regions and promotes hippocampal BDNF/serotonin signalling. This mechanism is entirely distinct from SSRIs, SNRIs, and tricyclic antidepressants.
Animal studies demonstrated rapid-onset (within 24 hours) antidepressant-like effects in forced swim, tail suspension, and unpredictable chronic mild stress paradigms. PE-22-28 also showed anxiolytic activity and promoted hippocampal neurogenesis. Its rapid onset distinguishes it from classical antidepressants with 2-4 week delays. Research extends to neuroprotection and cognitive resilience. Included in the Illumineuro Blend for its neurological wellness profile.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
